1.Management of abdominal aortic aneurysm in young adult
Xiaoxi LI ; Shengming WANG ; Songqi LI ; Weiming LV ; Yongjie LIN ;
Chinese Journal of General Surgery 2000;0(11):-
Objective To assess the clinical manifestation, management and outcome of abdominal aortic aneurysm (AAA) in young adult Methods Retrospective study was made on young AAA patients (
2.A study on“one-stop”premarital healthcare services based on SWOT analysis
Xiaoxi LIU ; Jiannan LV ; Fang WANG ; Xue DING ; Ting YANG ; Qiuxia SONG ; Li SONG ; Ying LIU
Chinese Journal of Health Policy 2016;9(5):13-18
Based on SWOT analysis and relevant information about the premarital healthcare services through on-site survey and literature research , this paper systematically analyzed the Strengths , Weaknesses , Opportunities and Threats of “one-stop” premarital healthcare services .It also puts forward some strategic suggestions on premarital healthcare services in China including enhancing communication and cooperation between the related national minis -tries and commissions , building a government-led multi-sectoral coordination mechanism , increasing the resource in-vestment , promoting the premarital health care service and pre-pregnancy physical examination integration , and strengthening publicity and mobilization of “one stop” service for premarital healthcare service policy recommenda-tions to provide a basis for decision-making in the promotion of the policy-related works .
3.A ESI-based analysis ofhot literatures on pharmacology & toxicology
Xia WANG ; Chuanlu LV ; Xiaoxi SUN
Journal of Pharmaceutical Practice 2016;34(5):437-440
Objective To analyze the outputof hotliteratures on pharmacology & toxicology in the world .Methods Es-sential Science Indicators Database were retrievedandthe national distribution ,published journals and hot research topics of hot literatures were analyzed .Results There were 76 papers in ESI on pharmacology & toxicology ,which were publishedin 22 countries or regions ,involved 5 hot research topics .Conclusion The influence of hot literatures on pharmacology & toxicology from China was behind European and American countries .Chinese journals should focus on the hot research on pharmacological& toxicology and improve the influence and scope of journals .
4.Simultaneous detection of 34 emerging contaminants in tap water by HPLC-MS/MS and health risk assessment
Yixuan CAO ; Ziwei YUAN ; Xiaoxi MU ; Chenshan LV ; Haiyan CUI ; Tao WANG ; Zhiwen WEI ; Zhongbing CHEN ; Hongyan ZOU ; Keming YUN ; Meng HU
Chinese Journal of Forensic Medicine 2024;39(1):31-38
Objective To establish a simultaneous detection approach for 34 emerging contaminants(ECs)in tap water by liquid chromatography-tandem mass spectrometry(HPLC-MS/MS).Human health risk assessment was performed according to the detection results from 43 tap water samples.Methods Tap water samples were concentrated and extracted by solid phase extraction,and then blown to near dry by nitrogen at 40℃.The sample extracts were dissolved in methanol-water solution(95:5,VN)to 0.5 mL for analyzing.Agilent Jet Stream Electrospray Ionization(AJS ESI)and the multiple reaction monitoring(MRM)mode were performed for MS to acquire the data of 34 ECs.A database including precursor ion,product ion and retention times was established accordingly.Results The average linear correlation coefficients(r)of 34 kinds of ECs was 0.995 9.The limits of detection were 0.01~0.60 ng/L and the recoveries were between 60.7%and 119.8%.The intra-group precisions were between 0.05%~9.89%and the intra-day precisions were between 0.20%~14.40%for the spiked samples.The method was applied to analyze 43 tap water samples and a total of 15 ECs were detected.According to the results,the detection rate of caffeine was the highest(84%),and the concentration range was ND~74.42 ng/L.Among all the ECs detected,1,2,3-benzotriazole had the highest concentration(ND~361.15 ng/L),where detection rate was 44%.Humans may be exposed to these ECs by drinking the tap water.The human health risk assessments of 12 kinds of ECs were carried out,however,the estimated risk was negligible(risk quotient<0.01).Conclusion The method is simple,highly sensitive and selective,and could meet the detection needs of ECs at trace level in tap water.There was no human health risk posed for ECs identified in 43 tap water samples analyzed by this method.
5.Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm.
Huimin YAN ; Bing CUI ; Xiaowei ZHANG ; Xiaoming FU ; Jun YAN ; Xiaoxing WANG ; Xiaoxi LV ; Zhong CHEN ; Zhuowei HU
Acta Pharmaceutica Sinica B 2015;5(3):176-187
Abdominal aortic aneurysm (AAA) is an inflammatory vascular disorder with high mortality. Accumulating evidence shows that toll-like receptor 2 (TLR2) plays a critical role in the regulation of wound-repairing process after tissue injury. We wondered if TLR2 signaling contributed to the pathogenesis of AAA and that targeting TLR2 would attenuate AAA development and progression. In this study, enhanced expression of TLR2 and its ligands were observed in human AAA tissue. Neutralization of TLR2 protected against AAA development and caused established AAA to regress in mouse models of AAA. In addition, TLR2-deficient mice also failed to develop AAA. The prophylactic and therapeutic effects of blocking TLR2 were accompanied by a significant resolution of inflammation and vascular remodeling, as indicated by the decreased expression or activity of MMP-2/9, α-SMA, inflammatory cytokines, and transcription factors NF-κB, AP-1 and STAT1/3 in AAA tissue. Mechanistically, blocking TLR2 decreased the expression and interaction of TLR2 and several endogenous ligands, which diminished chronic inflammation and vascular remodeling in the vascular tissue of AAA. Our studies indicate that the interactions between TLR2 and its endogenous ligands contribute to the pathogenesis of AAA and that targeting TLR2 offers great potential toward the development of therapeutic agents against AAA.
6.1,25-Dihydroxyvitamin D3 protects obese rats from metabolic syndrome promoting regulatory T cell-mediated resolution of inflammation.
Wen JIN ; Bing CUI ; Pingping LI ; Fang HUA ; Xiaoxi LV ; Jichao ZHOU ; Zhuowei HU ; Xiaowei ZHANG
Acta Pharmaceutica Sinica B 2018;8(2):178-187
Vitamin D has been found to produce therapeutic effects on obesity-associated insulin resistance and dyslipidemia through its potent anti-inflammatory activity, but the precise immunomodulatory mechanism remains poorly understood. In the present study we found that 1,25-dihydroxyvitamin D [1,25(OH)D], the biologically active form of vitamin D, significantly attenuated monosodium glutamate (MSG)-induced obesity and insulin resistance as indicated by body weight reduction, oral glucose tolerance improvement, and a glucose infusion rate increase as detected with hyperinsulinemic-euglycemic clamp. Moreover, 1,25(OH)D not only restored pancreatic islet functions but also improved lipid metabolism in insulin-targeted tissues. The protective effects of 1,25(OH)D on glycolipid metabolism were attributed to its ability to inhibit an obesity-activated inflammatory response in insulin secretory and targeted tissues, as indicated by reduced infiltration of macrophages in pancreas islets and adipose tissue while enhancing the expression of in liver tissue, which was accompanied by increased infiltration of Treg cells in immune organs such as spleen and lymph node as well as in insulin-targeted tissues such as liver, adipose, and muscle. Together, our findings suggest that 1,25(OH)D serves as a beneficial immunomodulator for the prevention and treatment of obesity or metabolic syndrome through its anti-inflammatory effects.
7.TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2.
Xiaoxi LV ; Shanshan LIU ; Chang LIU ; Yunxuan LI ; Tingting ZHANG ; Jie QI ; Ke LI ; Fang HUA ; Bing CUI ; Xiaowei ZHANG ; Yuxin LIU ; Jiaojiao YU ; Jinmei YU ; Li LI ; Xia LI ; Zhigang YAO ; Bo HUANG
Acta Pharmaceutica Sinica B 2023;13(4):1631-1647
Pulmonary fibrosis (PF) is the pathological structure of incurable fibroproliferative lung diseases that are attributed to the repeated lung injury-caused failure of lung alveolar regeneration (LAR). Here, we report that repetitive lung damage results in a progressive accumulation of the transcriptional repressor SLUG in alveolar epithelial type II cells (AEC2s). The abnormal increased SLUG inhibits AEC2s from self-renewal and differentiation into alveolar epithelial type I cells (AEC1s). We found that the elevated SLUG represses the expression of the phosphate transporter SLC34A2 in AEC2s, which reduces intracellular phosphate and represses the phosphorylation of JNK and P38 MAPK, two critical kinases supporting LAR, leading to LAR failure. TRIB3, a stress sensor, interacts with the E3 ligase MDM2 to suppress SLUG degradation in AEC2s by impeding MDM2-catalyzed SLUG ubiquitination. Targeting SLUG degradation by disturbing the TRIB3/MDM2 interaction using a new synthetic staple peptide restores LAR capacity and exhibits potent therapeutic efficacy against experimental PF. Our study reveals a mechanism of the TRIB3-MDM2-SLUG-SLC34A2 axis causing the LAR failure in PF, which confers a potential strategy for treating patients with fibroproliferative lung diseases.
8.The cell cycle inhibitor P21 promotes the development of pulmonary fibrosis by suppressing lung alveolar regeneration.
Xiaoxi LV ; Chang LIU ; Shanshan LIU ; Yunxuan LI ; Wanyu WANG ; Ke LI ; Fang HUA ; Bing CUI ; Xiaowei ZHANG ; Jiaojiao YU ; Jinmei YU ; ZhuoWei HU
Acta Pharmaceutica Sinica B 2022;12(2):735-746
The cell cycle inhibitor P21 has been implicated in cell senescence and plays an important role in the injury-repair process following lung injury. Pulmonary fibrosis (PF) is a fibrotic lung disorder characterized by cell senescence in lung alveolar epithelial cells. In this study, we report that P21 expression was increased in alveolar epithelial type 2 cells (AEC2s) in a time-dependent manner following multiple bleomycin-induced PF. Repeated injury of AEC2s resulted in telomere shortening and triggered P21-dependent cell senescence. AEC2s with elevated expression of P21 lost their self-renewal and differentiation abilities. In particular, elevated P21 not only induced cell cycle arrest in AEC2s but also bound to P300 and β-catenin and inhibited AEC2 differentiation by disturbing the P300-β-catenin interaction. Meanwhile, senescent AEC2s triggered myofibroblast activation by releasing profibrotic cytokines. Knockdown of P21 restored AEC2-mediated lung alveolar regeneration in mice with chronic PF. The results of our study reveal a mechanism of P21-mediated lung regeneration failure during PF development, which suggests a potential strategy for the treatment of fibrotic lung diseases.
9.S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung.
Mengyao HAO ; Rong FU ; Jun TAI ; Zhenhuan TIAN ; Xia YUAN ; Yang CHEN ; Mingjin WANG ; Huimin JIANG ; Ming JI ; Fangfang LAI ; Nina XUE ; Liping BAI ; Yizhun ZHU ; Xiaoxi LV ; Xiaoguang CHEN ; Jing JIN
Acta Pharmaceutica Sinica B 2023;13(3):1110-1127
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2-3 years and there is no effective intervention to treat IPF other than lung transplantation. As important components of lung tissue, endothelial cells (ECs) are associated with pulmonary diseases. However, the role of endothelial dysfunction in pulmonary fibrosis (PF) is incompletely understood. Sphingosine-1-phosphate receptor 1 (S1PR1) is a G protein-coupled receptor highly expressed in lung ECs. Its expression is markedly reduced in patients with IPF. Herein, we generated an endothelial-conditional S1pr1 knockout mouse model which exhibited inflammation and fibrosis with or without bleomycin (BLM) challenge. Selective activation of S1PR1 with an S1PR1 agonist, IMMH002, exerted a potent therapeutic effect in mice with bleomycin-induced fibrosis by protecting the integrity of the endothelial barrier. These results suggest that S1PR1 might be a promising drug target for IPF therapy.
10.TRIB3‒GSK-3
Shanshan LIU ; Xiaoxi LV ; Xupeng WEI ; Chang LIU ; Qiao LI ; Jiali MIN ; Fang HUA ; Xiaowei ZHANG ; Ke LI ; Pingping LI ; Yang XIAO ; Zhuowei HU ; Bing CUI
Acta Pharmaceutica Sinica B 2021;11(10):3105-3119
Pulmonary fibrosis (PF) is a chronic, progressive, fatal interstitial lung disease with limited available therapeutic strategies. We recently reported that the protein kinase glycogen synthase kinase-3